2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis

Joint Bone Spine

Volumn 81, Issue 6, 2014, Pages 493-501

  Briot, Karine ^a   Cortet, Bernard ^b   Roux, Christian ^a   Fardet, Laurence ^c   Abitbol, Vered ^a   Bacchetta, Justine ^d   Buchon, Daniel ^e   Debiais, Françoise ^f   Guggenbuhl, Pascal ^g   Laroche, Michel ^h   Legrand, Erik ⁱ   Lespessailles, Eric ^j   Marcelli, Christian ^k   Weryha, Georges ^l   Thomas, Thierry ^m  

^a Cochin hospital ^*  (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e Cabinet de Médecine Générale   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE RENNES 1   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^k CHU CÔTE DE NACRE   (France)

^l UNIVERSITY HOSPITAL OF NANCY   (France)

^m UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

more..

Author keywords

Bisphosphonates; Fracture; Glucocorticoids; Osteoporosis; Recommendations; Teriparatide

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PREDNISONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

AGE DISTRIBUTION; ANALGESIC ACTIVITY; ARTICLE; BODY MASS; BONE DENSITY; BONE STRENGTH; BONE TURNOVER; CALCIUM INTAKE; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMUR FRACTURE; FOLLOW UP; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; LONG TERM CARE; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PHYSICIAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; SPINE FRACTURE; TREATMENT DURATION; BONE; CHEMICALLY INDUCED; DRUG EFFECTS; PRACTICE GUIDELINE;

BONE AND BONES; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 84922507848     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.10.001     Document Type: Article

References (68)

1. Walsh L.J., Wong C.A., Pringle M., et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ 1996, 313:344-346.
2. Soucy E., Bellamy N., Adachi J.D., et al. A Canadian survey on the management of corticosteroid-induced osteoporosis by rheumatologists. J Rheumatol 2000, 27:1506-1512.
3. Fardet L., Petersen I., Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford) 2011, 50:1982-1990.
4. Díez-Pérez A., Hooven F.H., Adachi J.D., et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 2011, 49:493-498.
5. Kok C., Sambrook P.N. Secondary osteoporosis in patients with an osteoporotic fracture. Best Pract Res Clin Rheumatol 2009, 23:769-779.
6. Ramsey-Goldman R. Missed opportunities in physician management of glucocorticoid-induced osteoporosis?. Arthritis Rheum 2002, 46:3115-3120.
7. Buckley L.M., Marquez M., Hudson J.O., et al. Variations in physicians' judgments about corticosteroid-induced osteoporosis by physician specialty. J Rheumatol 1998, 25:2195-2202.
8. Guzman-Clark J.R., Fang M.A., Sehl M.E., et al. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum 2007, 57:140-146.
9. Solomon D.H., Katz J.N., Jacobs J.P., et al. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002, 46:3136-3142.
10. Duyvendak M., Naunton M., Atthobari J., et al. Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005. Osteoporos Int 2007, 18:1429-1433.
11. Brask-Lindemann D., Eiken P., Eskildsen P., et al. Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids. Osteoporos Int 2013, 24:1891-1897.
12. Wibaux C., Baudens G., Fiorentino-Devulder S., et al. Évolution de la prise en charge de l'ostéoporose cortisonique au sein du réseau rhumatisme inflammatoire chronique du Nord-Pas-de-Calais entre 2007 et 2010. Rev Rhum 2010, S77:A86.
13. Koetz K.R., Ventz M., Diederich S., et al. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012, 97:85-92. 10.1210/jc.2011-2036.
14. Grossman J.M., Gordon R., Ranganath V.K., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010, 62:1515-1526.
15. Lekamwasam S., Adachi J.D., Agnusdei D., et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012, 23:2257-2276.
16. Weinstein R.S. Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone 2010, 46:564-570.
17. Canalis E., Mazziotti G., Giustina A., et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
18. Weinstein R.S. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012, 41:595-611.
19. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
20. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309-2318.
21. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000, 15:1006-1013.
22. Laan R.F., van Riel P.L., van de Putte L.B., et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993, 119:963-968.
23. McKenzie R., Reynolds J.C., O'Fallon A., et al. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo-controlled trial. J Rheumatol 2000, 27:2222-2226.
24. Vis M., Havaardsholm E.A., Haugeberg G., et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1495-1499.
25. Wijbrandts C.A., Klaasen R., Dijkgraaf M.G., et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009, 68:373-376.
26. Van Staa T.P., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
27. Kanis J.A., Johansson H., Oden A., et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19:893-899.
28. Majumdar S.R., Morin S.N., Lix L.M., et al. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study. Osteoporos Int 2013, 9:2493-2498.
29. Angeli A., Guglielmi G., Dovio A., et al. High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006, 39:253-259.
30. de Vries F., Pouwels S., Lammers J.W., et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 2007, 261:170-177.
31. Kim S.Y., Schneeweiss S., Liu J., et al. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res 2012, 27:789-796.
32. Roussy J.P., Bessette L., Bernatsky S., et al. Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over. Osteoporos Int 2013, 24:2483-2492.
33. Ghazi M., Kolta S., Briot K., et al. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int 2012, 23:581-587.
34. Tatsuno I., Sugiyama T., Suzuki S., et al. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab 2009, 94:1671-1677.
35. Van Staa T.P., Geusens P., Pols H.A., et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005, 98:191-198.
36. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1999, 339:292-299.
37. Adachi J.D., Saag K.G., Delmas P.D., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44:202-211.
38. Thompson J.M., Modin G.W., Arnaud C.D., et al. Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density. Calcif Tissue Int 1997, 61:377-381.
39. van Staa T.P., Geusens P., Bijlsma J.W., et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3104-3112.
40. Van Staa T.P., Laan R.F., Barton I.P., et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
41. Kanis J.A., Johnell O., Oden A., et al. FRAX® and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
42. Kanis J.A., Johansson H., Oden A., et al. Guidance for the adjustment of FRAX® according to the dose of glucocorticoids. Osteoporos Int 2011, 22:809-816.
43. Leib E.S., Saag K.G., Adachi J.D., et al. Official Positions for FRAX® clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX® of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). J Clin Densitom 2011, 14:212-219.
44. Schousboe J.T., Vokes T., Broy S.B., et al. Vertebral fracture assessment: the 2007 ISCD official positions. J Clin Densitom 2008, 11:92-108.
45. Briot K., Cortet B., Thomas T., et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012, 79:304-313.
46. El-Khoury F., Cassou B., Charles M.A., et al. The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials. BMJ 2013, 347:f6234.
47. Bolland M.J., Barber P.A., Doughty R.N., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008, 336:262-266.
48. Bolland M.J., Avenell A., Baron J.A., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
49. Pentti K., Tuppurainen M.T., Honkanen R., et al. Use of calcium supplementation and the risk of coronary heart disease in 52-62-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. Maturitas 2009, 63:73-78.
50. Bolland M.J., Grey A., Avenell A., et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011, 342:d2040. 10.1136/bmj.d2040.
51. Lewis J.R., Calver J., Zhu K., et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011, 26:35-41.
52. Benhamou C.L., Souberbielle J.C., Cortet B., et al. La vitamine D chez l'adulte: recommandations du GRIO. Presse Med 2011, 40:673-682.
53. Sanders K.M., Stuart A.L., Williamson E.J., et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303:1815-1822.
54. Roux C., Oriente P., Laan R., et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998, 83:1128-1133.
55. Adachi J.D., Roux C., Pitt P.I., et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid-induced bone loss. J Rheumatol 2000, 27:2424-2431.
56. Wallach S., Cohen S., Reid D.M., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277-285.
57. Reid D.M., Devogelaer J.P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263.
58. Sambrook P.N., Roux C., Devogelaer J.P., et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012, 50:289-295.
59. Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
60. Saag K.G., Zanchetta J.R., Devogelaer J.P. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60:3346-3355.
61. Kanis J.A., Stevenson M., McCloskey E.V., et al. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2007, 11:iii-iv. [ix-xi, 1-231].
62. Tosteson A.N., Melton L.J., Dawson-Hughes B., et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008, 19:437-447.
63. Homik J., Cranney A., Shea B., et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 2000, 2:CD001347.
64. Briot K., Legrand E., Pouchain D., et al. Accuracy of patient-reported height loss and risk factors for height loss among postmenopausal women. CMAJ 2010, 6:558-562.
65. Siminoski K., Warshawski R.S., Jen H., et al. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women. Osteoporos Int 2006, 17:290-296.
66. Shane E., Burr D., Abrahamsen B., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2013, 10.1002/jbmr.1998.
67. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010, 47:169-180.
68. Schilcher J., Michaëlsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.